Amgen sues Hospira for infringement of Neulasta patent

Feb 11, 2020

On 11 February 2020, Amgen sued Hospira in the District Court of Delaware, alleging Hospira’s aBLA for a proposed pegfilgrastim biosimilar infringes Amgen’s Neulasta patent for protein purification (no. 8,273,707).

Print Page Mail Article